Drug Trial Radar · NCT06490445
A Study of Medical Cannabis Aerosol Via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
122
Actual
Start
Nov 14, 2024
Primary completion
May 26, 2026
Study completion Jun 24, 2026
Sponsor
- Lead sponsor
- Syqe MedicalIndustry
- Sponsor type
- Industry
- First posted
- Jul 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the safety and efficacy of medical cannabis aerosol containing 0.25, 0.50, 1.0 milligrams (mg) delta (Δ) 9-tetrahydrocannabinol (THC) inhaled three times a day (TID) compared to placebo via the Fixed-dose Syqe Inhaler on pain intensity at Week 15.
Conditions
- Diabetic Peripheral Neuropathic Pain
Interventions
Medical CannabisDrug
Syqe cartridge containing medical cannabis (Bedrocan®) administered using Fixed-dose Syqe Inhaler.
PlaceboDrug
Placebo administered using Fixed-dose Syqe Inhaler.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Weekly-mean 24-hour Average Pain Score on the Numeric Rating Scale (NRS) at Week 15Time frame: Baseline and at Week 15
Locations
38 sites in 5 countries. Site status is shown where the registry gives one.
Innovate Clinical Research
Waitara, New South Wales, Australia
Western Sydney University NICM Health Research Institute (NICM HRI)
Westmead, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Emeritus Research
Camberwell, Victoria, Australia
The Royal Melbourne Hospital
Parkville, Victoria, Australia
Rychnov nad Kneznou, Hradec Kralove
Rychnov nad Kněžnou, Hradec Kralove, Czechia
Ostrava, Ostrava City
Ostrava, Ostrava City, Czechia
Plzen, Plzen City
Pilsen, Plzen City, Czechia
Prague, Praha 12
Prague, Prague, Czechia
Klinische Forschung Dresden GmbH
Dresden, Germany
Klinische Forschung Schwerin GmbH
Schwerin, Germany
Heidelberg, Baden-Wuerttemberg
Heidelberg, Baden-Wurttemberg, Germany
Karlsruhe, Baden-Württemberg
Karlsruhe, Baden-Wurttemberg, Germany
Ulm, Baden-Württemberg
Ulm, Baden-Wurttemberg, Germany
Hamburg, Hamburg
Hamburg, Free and Hanseatic City of Hamburg, Germany
Hannover, Lower Saxony
Hanover, Lower Saxony, Germany
Schwerin, Mecklenburg
Schwerin, Mecklenburg, Germany
Reinfeld, Schleswig-Holstein
Reinfeld, Schleswig-Holstein, Germany
Berlin, Berlin 4010
Berlin, State of Berlin, Germany
Berlin, Berlin
Berlin, State of Berlin, Germany
Barzilai Medical center
Ashkelon, Israel
Bnai Zion Medical Center
Haifa, Israel
Rambam Medical Center
Haifa, Israel
Hadassah Medical Center
Jerusalem, Israel
Beilinson hospital/ Petach Tikva
Petah Tikva, Israel
Ziv Medical Center
Safed, Israel
The Edith Wolfson Medical Center
Holon, Tel Aviv, Israel
Sheba Medical center Hospital
Ramat Gan, Tel Aviv, Israel
Centrum Medyczne NEUROMED
Bydgoszcz, Poland
Centrum Medyczne Pratia Chojnice
Chojnice, Poland
Osrodek Badan Klinicznych Neuro-Medic Clinic
Katowice, Poland
Swidnica, Dolnoslaskie
Swidnica, Lower Silesian Voivodeship, Poland
Sochaczew, Mazowieckie
Sochaczew, Masovian Voivodeship, Poland
Warszawa, Mazowieckie 7011
Warsaw, Masovian Voivodeship, Poland
Warszawa, Mazowieckie
Warsaw, Masovian Voivodeship, Poland
Warszawa, Mazowieckie 7010
Warsaw, Masovian Voivodeship, Poland
Katowice, Silesia
Katowice, Silesian Voivodeship, Poland
Katowice, Śląsk
Katowice, Silesian Voivodeship, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.